| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2141.2005.05674.X |
| P698 | PubMed publication ID | 16115126 |
| P50 | author | Eleftheria Hatzimichael | Q73418790 |
| P2093 | author name string | Justin Stebbing | |
| Konstantinos L Bourantas | |||
| Afroditi Katsaraki | |||
| Konstantinos Seferiadis | |||
| Katerina E Panteli | |||
| Paraskevi K Bouranta | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 709-715 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases | |
| P478 | volume | 130 |
| Q38715127 | A myeloid tumor suppressor role for NOL3 |
| Q53720651 | Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F. |
| Q40978238 | Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers. |
| Q39554914 | Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor |
| Q40544293 | Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. |
| Q33944270 | CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms |
| Q34416807 | Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment |
| Q40564541 | Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly |
| Q26777398 | Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest |
| Q90329840 | Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures |
| Q36776428 | Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. |
| Q26778929 | Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms |
| Q60907870 | Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm |
| Q42602569 | Detection of Serum microRNAs From Department of Defense Serum Repository: Correlation With Cotinine, Cytokine, and Polycyclic Aromatic Hydrocarbon Levels |
| Q58567518 | Diagnostic Problems in Chronic Basophilic Leukemia |
| Q38999178 | Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts |
| Q33404574 | Emerging drugs for myelofibrosis |
| Q64933278 | Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. |
| Q26778326 | Guidelines for the management of myeloproliferative neoplasms |
| Q39202346 | Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine |
| Q36177495 | Hyperinsulinemia and insulin resistance in a patient with type 2 diabetes complicated with myelofibrosis. |
| Q41887599 | Impacts of K562 cells towards activities of Toll-like receptor pathway of human mesenchymal stem cell-bone marrow. |
| Q34576982 | Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia |
| Q34543068 | Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. |
| Q97545559 | Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia |
| Q34253316 | Mast cell leukemia associated with undefined morphology and chronic basophilic leukemia |
| Q41576528 | Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development |
| Q53818544 | Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. |
| Q38725723 | Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both |
| Q33411763 | Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing |
| Q28211546 | Polycythaemia vera and essential thrombocythaemia: current treatment strategies |
| Q34021151 | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms |
| Q36150377 | Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms. |
| Q33843736 | Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia |
| Q33391880 | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis |
| Q55334343 | Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells. |
| Q92179587 | Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling |
| Q53206022 | TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. |
| Q42085145 | TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders |
| Q26778931 | The Hen or the Egg: Inflammatory Aspects of Murine MPN Models |
| Q35571892 | The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow |
| Q38083604 | The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation |
| Q60044478 | The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms |
| Q43289306 | The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas |
| Q37705695 | Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis |
| Q40679370 | Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis |
| Q89927111 | miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk |
Search more.